HRP20201902T1 - Pripravci protiv raka - Google Patents
Pripravci protiv raka Download PDFInfo
- Publication number
- HRP20201902T1 HRP20201902T1 HRP20201902TT HRP20201902T HRP20201902T1 HR P20201902 T1 HRP20201902 T1 HR P20201902T1 HR P20201902T T HRP20201902T T HR P20201902TT HR P20201902 T HRP20201902 T HR P20201902T HR P20201902 T1 HRP20201902 T1 HR P20201902T1
- Authority
- HR
- Croatia
- Prior art keywords
- solid dispersion
- formulation
- arn
- poly
- meth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 16
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000007962 solid dispersion Substances 0.000 claims 16
- 238000009472 formulation Methods 0.000 claims 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 9
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims 8
- 229920000193 polymethacrylate Polymers 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000006185 dispersion Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229960004103 abiraterone acetate Drugs 0.000 claims 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000009474 hot melt extrusion Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 239000006104 solid solution Substances 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (28)
1. Kruta disperzija koja sadrži
[image]
i kopolimer poli(met)akrilat.
2. Kruta disperzija prema patentnom zahtjevu 1 naznačena time što se disperzija sastoji od ARN-509 i kopolimera poli(met)akrilata.
3. Kruta disperzija prema patentnom zahtjevu 1 ili 2 naznačena time što je maseni omjer ARN-509 : kopolimer poli(met)akrilat u krutoj disperziji u rasponu od 1 : 1 do 1 : 5.
4. Kruta disperzija prema patentnom zahtjevu 3 naznačena time što maseni omjer ARN-509 : kopolimer poli(met)akrilat u krutoj disperziji iznosi 1:2.
5. Kruta disperzija prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što je ARN-509 prisutan u amorfnom obliku.
6. Kruta disperzija prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što je disperzija kruta otopina.
7. Kruta disperzija prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što kopolimer poli(met)akrilat je poli(metakrilna kiselina-ko-etil akrilat) 1:1.
8. Kruta disperzija prema bilo kojem od prethodnih patentnih zahtjeva naznačena time što se može dobiti sušenjem raspršivanjem.
9. Kruta disperzija prema bilo kojem od patentnih zahtjeva 1 do 7 naznačena time što se može dobiti ekstruzijom vruće taljevine.
10. Čestica koja se sastoji od krute disperzije kako je definirana u bilo kojem od prethodnih zahtjeva.
11. Čestica koja naznačena time što sadrži krutu disperziju kako je definirana u bilo kojem od zahtjeva 1 do 9.
12. Farmaceutska formulacija naznačena time što sadrži farmaceutski prihvatljiv nosač i krutu disperziju prema bilo kojem od patentnih zahtjeva 1 do 9.
13. Farmaceutska formulacija naznačena time što sadrži farmaceutski prihvatljiv nosač i česticu prema patentnom zahtjevu 10 ili 11.
14. Formulacija prema patentnom zahtjevu 12 ili 13 naznačena time što formulacija sadrži 60 mg ARN-509.
15. Formulacija prema patentnom zahtjevu 12 ili 13 naznačena time što formulacija sadrži 120 mg ARN-509.
16. Formulacija prema patentnom zahtjevu 12 ili 13 naznačena time što formulacija sadrži 240 mg ARN-509.
17. Formulacija bilo kojem od patentnih zahtjeva 12 to 16 naznačena time što se masa krute disperzije kreće u rasponu od 20 do 40% ukupne mase formulacije.
18. Formulacija bilo kojem od patentnih zahtjeva 12 do 17 naznačena time što je formulacija tableta.
19. Formulacija prema patentnom zahtjevu 18 naznačena time što je pogodna za oralnu primjenu.
20. Postupak pripreme krute disperzije prema patentnom zahtjevu 8 naznačen time što sadrži korake miješanja ARN-509 i kopolimera poli(met)akrilat u prikladnom otapalu i sušenje raspršivanjem navedene smjese.
21. Postupak prema patentnom zahtjevu 20 naznačen time što je prikladno otapalo smjesa diklormetana i metanola.
22. Postupak prema patentnom zahtjevu 21 naznačen time što omjer mase diklormetana i metanola u smjesi diklorometana prema metanolu u smjesi iznosi 5:5.
23. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 12 do 19 naznačena time što se koristi u liječenju karcinoma prostate.
24. Farmaceutska formulacija za uporabu prema patentnom zahtjevu 23 naznačena time što je formulacija za oralnu primjenu.
25. Kombinacija farmaceutske formulacije prema bilo kojem od patentnih zahtjeva 12 do 19 i drugog sredstva protiv raka.
26. Kombinacija prema patentnom zahtjevu 25 naznačena time što je drugo sredstvo protiv raka inhibitor biosinteze androgena.
27. Kombinacija prema patentnom zahtjevu 25 naznačena time što je drugo sredstvo protiv raka abirateron acetat.
28. Kombinacija prema bilo kojem od patentnih zahtjeva 25 do 27 naznačena time što nadalje sadrži prednizon.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196591 | 2014-12-05 | ||
| PCT/US2015/063667 WO2016090101A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
| EP15817642.0A EP3226842B1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201902T1 true HRP20201902T1 (hr) | 2021-07-23 |
Family
ID=52006905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201902TT HRP20201902T1 (hr) | 2014-12-05 | 2020-11-30 | Pripravci protiv raka |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20170360707A1 (hr) |
| EP (2) | EP3842034A1 (hr) |
| JP (1) | JP6767368B2 (hr) |
| KR (1) | KR102348325B1 (hr) |
| CN (2) | CN106999430A (hr) |
| AR (1) | AR102924A1 (hr) |
| AU (1) | AU2015358493B2 (hr) |
| CA (1) | CA2969661C (hr) |
| CL (1) | CL2017001372A1 (hr) |
| CO (1) | CO2017005573A2 (hr) |
| CR (1) | CR20170217A (hr) |
| CY (1) | CY1123856T1 (hr) |
| DK (1) | DK3226842T3 (hr) |
| EA (1) | EA035988B1 (hr) |
| ES (1) | ES2839128T3 (hr) |
| HR (1) | HRP20201902T1 (hr) |
| HU (1) | HUE051888T2 (hr) |
| IL (1) | IL252324B (hr) |
| LT (1) | LT3226842T (hr) |
| MA (2) | MA41108B1 (hr) |
| MD (1) | MD3226842T2 (hr) |
| MX (1) | MX2017007201A (hr) |
| NI (1) | NI201700069A (hr) |
| PL (1) | PL3226842T3 (hr) |
| PT (1) | PT3226842T (hr) |
| RS (1) | RS61466B1 (hr) |
| SG (1) | SG11201704264UA (hr) |
| SI (1) | SI3226842T1 (hr) |
| TW (1) | TWI683662B (hr) |
| UA (1) | UA121123C2 (hr) |
| WO (1) | WO2016090101A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202190820A1 (ru) | 2012-09-26 | 2021-10-29 | Арагон Фармасьютикалз, Инк. | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты |
| MX2017007206A (es) | 2014-12-05 | 2018-01-30 | Aragon Pharmaceuticals Inc | Composiciones anticancerigenas. |
| WO2019078920A1 (en) | 2017-10-16 | 2019-04-25 | Aragon Pharmaceuticals, Inc. | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER |
| EP3773509B1 (en) * | 2018-04-06 | 2023-11-01 | Capsugel Belgium NV | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
| WO2020144650A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of prostate cancer |
| BR112021014969A2 (pt) | 2019-01-30 | 2021-10-05 | Aragon Pharmaceuticals, Inc. | Antiandrogênios para o tratamento de câncer de próstata metastático sensível à castração |
| WO2020157704A1 (en) | 2019-01-30 | 2020-08-06 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| EP4054572A1 (en) | 2019-11-04 | 2022-09-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| WO2024189186A1 (en) | 2023-03-16 | 2024-09-19 | Bayer Consumer Care Ag | Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002080902A1 (en) | 2001-04-02 | 2002-10-17 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
| WO2003077827A1 (fr) * | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Procede de production de medicament solide en dispersion |
| EP1694302A1 (en) * | 2003-12-15 | 2006-08-30 | Council of Scientific and Industrial Research | TASTE MASKED PHARMACEUTICAL COMPOSITIONS COMPRISING BITTER DRUG AND pH SENSITIVE POLYMER |
| PL3412290T3 (pl) * | 2006-03-27 | 2021-09-06 | The Regents Of The University Of California | Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym |
| HUE037389T2 (hu) * | 2010-02-16 | 2018-08-28 | Aragon Pharmaceuticals Inc | Androgén receptor modulátorok és alkalmazásaik |
| CA2839301C (en) * | 2011-06-15 | 2021-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2013152342A1 (en) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| PE20200725A1 (es) | 2012-06-07 | 2020-07-21 | Aragon Pharmaceuticals Inc | Formas cristalinas del modulador receptor de androgeno: 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-diazaespiro[3,4]oct-5-il]-2-fluoro-n-metilbenzamida) (apalutamida) |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| SI3725778T1 (sl) * | 2012-09-11 | 2022-02-28 | Medivation Prostate Therapeutics Llc | Formulacije enzalutamida |
| EA202190820A1 (ru) * | 2012-09-26 | 2021-10-29 | Арагон Фармасьютикалз, Инк. | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| KR101737250B1 (ko) * | 2013-01-22 | 2017-05-17 | 에프. 호프만-라 로슈 아게 | 개선된 생체이용률을 갖는 약학 조성물 |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| RU2016104643A (ru) * | 2013-08-12 | 2017-09-19 | Токай Фармасьютикалз, Инк. | Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения |
| AU2015215000B2 (en) * | 2014-02-05 | 2017-10-19 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
-
2015
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh active
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 EP EP20209559.2A patent/EP3842034A1/en active Pending
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active IP Right Grant
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/en active Active
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/en active Application Filing
- 2015-12-03 MX MX2017007201A patent/MX2017007201A/es unknown
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 CN CN202211487545.0A patent/CN115837010A/zh active Pending
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 CA CA2969661A patent/CA2969661C/en active Active
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro unknown
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
-
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
-
2020
- 2020-11-30 HR HRP20201902TT patent/HRP20201902T1/hr unknown
-
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/661,226 patent/US20240293321A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201902T1 (hr) | Pripravci protiv raka | |
| HRP20211140T1 (hr) | Pripravci protiv raka | |
| JP2017536407A5 (hr) | ||
| JP2017536401A5 (hr) | ||
| HRP20200326T1 (hr) | Formulacija koja sadrži čestice | |
| Li et al. | In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets | |
| Mundargi et al. | Encapsulation and controlled release formulations of 5-fluorouracil from natural Lycopodium clavatum spores | |
| JP2014516080A5 (hr) | ||
| PH12014502340A1 (en) | A delayed release drug formulation | |
| PH12021550603A1 (en) | Compositions and methods of manufacturing protein microparticles | |
| MX2016007134A (es) | Composiciones farmaceuticas mejoradas de pimobendan. | |
| MX2015012887A (es) | Composiciones de un poliortoester y un solvente aprotico. | |
| PE20181925A1 (es) | Composiciones antineoplasicas | |
| HRP20200780T1 (hr) | Formulacija za kontrolirano otpuštanje hidrokortizona | |
| HRP20161340T1 (hr) | Formulacije darunavira | |
| HRP20240033T1 (hr) | Formulacija koja sadrži inhibitor mek | |
| RU2016102605A (ru) | Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин | |
| JP2018516910A5 (hr) | ||
| JP2015510935A5 (hr) | ||
| PH12018500304A1 (en) | A delyade release drug formulation | |
| CN102440963A (zh) | 一种别嘌醇缓释微丸及其制备方法 | |
| HRP20150410T1 (hr) | Novi pripravci za terapiju esencijalne trombocitemije | |
| WO2014111956A3 (en) | Sustained release formulations of curcuminoids and method of preparation thereof | |
| CN102406619A (zh) | 一种缓释微丸及其制备方法 | |
| AR081929A1 (es) | Formulaciones de levetiracetam de liberacion controlada y metodos para su produccion |